TScan Therapeutics, Inc.
Business
TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer and autoimmune disorders. The company's lead product candidate, TSC-101, targets HA-2 antigen in patients with acute myeloid leukemia and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. TScan operates three primary programs: hematologic malignancies (TSC-101 and CD45-targeting candidates), solid tumors (multiplex TCR-T therapies targeting HPV16, MAGE-A4, and PRAME), and autoimmune disorders (targeting ankylosing spondylitis, ulcerative colitis, and scleroderma). The company manufactures clinical product in-house using a transposon-based non-viral platform and has engaged a contract development and manufacturing organization for commercial-scale production.
Summary from 10-K filed 2026-03-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration and license revenue | 10 | 3 | 21 | 14 | 10 | |
| Research and development | 114 | 107 | 88 | 60 | 45 | |
| General and administrative | 32 | 30 | 26 | 20 | 14 | |
| Total operating expenses | 146 | 138 | 115 | 80 | 59 | |
| Loss from operations | −136 | −135 | −93 | −67 | −49 | |
| Interest and other income, net | 9 | 12 | 8 | 2 | 16,000 | |
| Interest expense | −3 | −4 | −4 | −1 | — | |
| Loss on extinguishment of debt | — | −1 | — | — | — | |
| Total other income | 6 | 7 | 4 | 415,000 | 16,000 | |
| Net Loss | −130 | −128 | −89 | −66 | −49 | |
| Net loss per share, basic | −1 | −1.14 | −1.36 | −2.75 | −4.17 | |
| Net loss per share, diluted | −1 | −1.14 | −1.36 | −2.75 | −4.17 | |
| Weighted average common shares outstanding- basic | 130 | 112 | 66 | 24 | 12 | |
| Weighted average common shares outstanding-diluted | 130 | 112 | 66 | 24 | 12 | |
| Unrealized gain (loss) on available-for-sale securities | −51,000 | 51,000 | — | — | — | |
| Comprehensive loss | −130 | −127 | −89 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-10-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 152 | 179 | 133 | 120 | — | |
| Marketable securities | — | 111 | 59 | — | — | |
| Prepaid expenses and other current assets | 5 | 3 | 2 | 4 | — | |
| Total current assets | 157 | 293 | 194 | 124 | — | |
| Property and equipment, net | 9 | 7 | 8 | 10 | — | |
| Right-of-use assets | 58 | 64 | 63 | 59 | 58 | |
| Restricted cash | 5 | 5 | 5 | 5 | — | |
| Long-term deposit and other assets | 101,000 | 2 | 2 | 725,000 | — | |
| Total assets | 229 | 371 | 272 | 199 | — | |
| Accounts payable | 1 | 4 | 2 | 3 | — | |
| Accrued expenses and other current liabilities | 8 | 15 | 11 | 7 | — | |
| Operating lease liability, current portion | 7 | 5 | 3 | 4 | — | |
| Deferred revenue, current portion | 3 | 12 | 10 | 4 | — | |
| Total current liabilities | 19 | 36 | 30 | 17 | — | |
| Deferred revenue, net of current portion | — | 1 | 6 | — | — | |
| Operating lease liability, net of current portion | 54 | 61 | 59 | 53 | — | |
| Long-term debt and accrued interest | 33 | 32 | 27 | 29 | — | |
| Other long term liabilities | — | 135,000 | — | 49,000 | — | |
| Total liabilities | 106 | 130 | 121 | 100 | — | |
| Commitments and contingencies (Note 10) | — | — | — | — | — | |
| Additional paid-in capital | 628 | 616 | 398 | 258 | — | |
| Accumulated other comprehensive income | — | 51,000 | — | — | — | |
| Accumulated deficit | −505 | −375 | −248 | −158 | — | |
| Total stockholders' equity | 123 | 241 | 151 | 99 | — | |
| Total liabilities and stockholders' equity | 229 | 371 | 272 | 199 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −130 | −127 | −89 | −66 | −49 | |
| Depreciation expense | 3 | 4 | 5 | 5 | 3 | |
| Accretion of marketable securities | −2 | −4 | −1 | — | — | |
| Non-cash interest expense related to loan payable | 462,000 | 773,000 | 757,000 | — | — | |
| Stock-based compensation | 12 | 10 | 5 | 5 | 3 | |
| Prepaid expenses and other assets | −525,000 | −538,000 | 985,000 | −410,000 | −3 | |
| Right-of-use assets and lease liabilities, net | 3 | 2 | 935,000 | −2 | −9,000 | |
| Accounts payable | −3 | 2 | −52,000 | 528,000 | 10,000 | |
| Accrued expense and other liabilities | −7 | 5 | 4 | 732,000 | 3 | |
| Deferred revenue | −10 | −3 | 12 | −9 | −7 | |
| Net cash used in operating activities | −135 | −111 | −61 | −67 | −49 | |
| Purchases of property and equipment | −4 | −4 | −3 | −4 | −10 | |
| Purchases of marketable securities | −87 | −241 | −78 | — | — | |
| Proceeds from maturities of marketable securities | 201 | 193 | 20 | — | — | |
| Net cash provided by (used in) investing activities | 109 | −53 | −61 | −4 | −10 | |
| Repayment of loan payable, net | — | −17 | — | — | — | |
| Proceeds from borrowings under loan agreement, net | — | 32 | — | — | — | |
| Proceeds from issuance of common stock, net of offering costs | — | 33 | 42 | 193,000 | — | |
| Proceeds from issuance of pre-funded warrants, net of offering costs | — | 158 | 92 | — | — | |
| Issuance of common stock under employee stock purchase plan | 264,000 | 333,000 | — | 193,000 | — | |
| Proceeds from exercise of stock options | — | 2 | 711,000 | 133,000 | 291,000 | |
| Cash paid for debt issuance costs | −400,000 | — | — | — | — | |
| Cash paid for financing costs | −200,000 | — | — | — | — | |
| Net cash provided by (used in) financing activities | −336,000 | 209 | 135 | 29 | 190 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −26 | 45 | 13 | −41 | 131 | |
| Cash paid for interest | 2 | 3 | 3 | 660,000 | — | |
| Debt issuance costs not yet paid | — | 400,000 | — | — | — | |
| Financing costs not yet paid | — | 200,000 | — | — | — | |
| Lease liability arising from obtaining right-of-use asset | — | 6 | 6 | 54 | — | |
| Purchase of property and equipment in accounts payable and accrued liabilities | 7,000 | 84,000 | 301,000 | 444,000 | 828,000 | |
| Issuance of common stock upon note conversion | — | 15 | — | — | 159 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is TScan Therapeutics, Inc.'s CIK number?
TScan Therapeutics, Inc.'s SEC CIK number is 0001783328 (1783328). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find TScan Therapeutics, Inc.'s SEC filings?
All of TScan Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did TScan Therapeutics, Inc. last report earnings?
TScan Therapeutics, Inc. (TCRX) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-207549). This is TScan Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is TScan Therapeutics, Inc.'s most recent earnings 8-K?
TScan Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001193125-26-207549. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View TScan Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →